FindMyKOL
Clinical trialNCT03878524TerminatedPhase 1Interventional

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

SponsorOHSU Knight Cancer InstituteEnrollment2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin Lymphoma+44 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Ohsu Knight Cancer Institute

    Portland, Oregon, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Abemaciclib →Abiraterone →Afatinib →Bevacizumab →Bicalutamide →Bortezomib →Cabazitaxel →Cabozantinib →Capecitabine →Carboplatin →Celecoxib →Cobimetinib →Copanlisib →Dabrafenib →Dacomitinib →Darolutamide →Dasatinib →Doxorubicin →Durvalumab →Enasidenib →Entrectinib →Enzalutamide →Erlotinib →Everolimus →Fluorouracil →Idelalisib →Imatinib →Ipilimumab →Lenvatinib →Leucovorin →Lorlatinib →Losartan →Paclitaxel →Neratinib →Nivolumab →Olaparib →Oxaliplatin →Palbociclib →Panobinostat →Pembrolizumab →Pertuzumab →Ponatinib →Regorafenib →Ruxolitinib →Sirolimus →Sorafenib →Sunitinib →Trametinib →Trastuzumab →Tretinoin →Vemurafenib →Venetoclax →Vismodegib →Vorinostat →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Apr 2020
Primary completion
10 Dec 2020
Completion
10 Dec 2020
Last update posted
4 Mar 2024
Registered enrollment
2
Registry id
NCT03878524
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.